T-ALL lines pre-treated with NAD+ were resistant to FK866 but sensitive to doxorubicin, confirming that the observed rescue from cytotoxicity by NAD + pre-treatment was specific to the NAMPT inhibitor FK866 (Fig 1C). The gene discussed is NAMPT; the disease is acute lymphoblastic leukemia.